CSL INDONESIA ALBAPURE 20 human albumin 20% (200g/L) injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Albumin, Quantity: 200 g/L

Available from:

CSL Behring Australia Pty Ltd

INN (International Name):

Albumin

Pharmaceutical form:

Injection, solution

Composition:

Excipient Ingredients: sodium; octanoate

Administration route:

Intravenous

Units in package:

50 mL, 100 mL

Prescription type:

(S1) This Schedule is intentionally blank

Therapeutic indications:

Hypoproteinaemia in the acutely ill patient - Albapure 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. Shock - Albapure 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma. Severe Burns - Extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. Iso-oncotic albumin solution is the preferred replacement material. If the patient's serum albumin level is not maintained, concentrated albumin (20%) may be indicated. If exchange occurs less frequently than once a week, less concentrated colloids may be appropriate.

Product summary:

Visual Identification: Clear, slightly viscous almost colourless, yellow or green solution; Container Type: Vial; Container Life Time: 4 Years; Container Temperature: Store below 30 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2007-02-07